Sector News

Horizon Pharma in $800M Raptor rare disease buy

September 13, 2016
Life sciences

Ireland’s Horizon Pharma will pay a 21% premium for California-based Raptor Pharmaceutical as it looks to bolster its rare disease portfolio while also expanding its geographical footprint. But it will also gain a tough pipeline that has been hit by failures over the past year.

The deal, which is worth $9 a share–or around $800 million–will see Horizon gain access to Procysbi (cysteamine bitartrate) for the orphan condition nephropathic (kidney) cystinosis, as well as Quinsair, which is licensed in Europe and Canada to help manage chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.

The merger will also diversify Horizon’s revenue with 11 medicines across three business units, namely in orphan, rheumatology and primary care–as well as bolstering its rare disease revenue, which in the first 6 months of 2016 was nearly half of Horizon’s total revenue.

The deal should be done by the end of the year. This will be good news to Novato, CA-based Raptor, which last year pulled the plug on its drug for NASH and then said it would be pushing ahead with a pivotal study for a new drug to treat Huntington’s even though it failed the primary endpoint in a Phase II/III trial.

“The proposed acquisition of Raptor furthers our commitment to helping people with rare diseases and is a significant step in advancing our strategy to expand our rare disease business,” said Timothy Walbert, chairman, president and CEO of Horizon.

“Along with the potential for accelerated revenue growth, the addition of Raptor strengthens our U.S. orphan business and provides a platform to expand our orphan business in Europe and other key international markets. We look forward to working with new patient communities and building on the success of the Raptor team.”

“This transaction will deliver significant and immediate value to our shareholders through a compelling all-cash premium and provide ongoing value to our patients, their families and the physicians who treat them,” added Julie Anne Smith, president and CEO of Raptor.

Horizon said it will pay for most of the transaction, namely $675 million, through external debt, along with cash on hand for the rest. As of June 30, 2016, the company had $424.5 million of cash and cash equivalents on its balance sheet, it said in a statement, with a market cap of around $2.8 billion.

Horizon was down 1.5% premarket on the news this morning, while Raptor was up 20% premarket to $7.45 a share.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.